News articles about Cryolife (NYSE:CRY) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cryolife earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 44.0186505825909 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Cryolife (NYSE:CRY) opened at $18.20 on Wednesday. The firm has a market cap of $623.98, a P/E ratio of 65.00 and a beta of 0.82. Cryolife has a 1-year low of $14.02 and a 1-year high of $24.00. The company has a quick ratio of 4.90, a current ratio of 5.96 and a debt-to-equity ratio of 0.29.

Cryolife (NYSE:CRY) last issued its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. The firm had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.60 million. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm’s revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share. equities analysts forecast that Cryolife will post 0.28 EPS for the current year.

Several analysts have recently issued reports on CRY shares. Lake Street Capital increased their price target on shares of Cryolife to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Canaccord Genuity reissued a “buy” rating and set a $25.00 price target on shares of Cryolife in a research report on Monday, October 9th. Northland Securities reissued a “buy” rating and set a $23.50 price target on shares of Cryolife in a research report on Monday, November 13th. TheStreet cut shares of Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Finally, Zacks Investment Research raised shares of Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $23.63.

In related news, CAO Amy Horton sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the sale, the chief accounting officer now owns 98,705 shares of the company’s stock, valued at $1,875,395. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO David Ashley Lee sold 33,190 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $630,610.00. Following the completion of the sale, the chief financial officer now directly owns 324,339 shares in the company, valued at approximately $6,162,441. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,190 shares of company stock worth $1,138,240. 6.00% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This article was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2018/01/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-cryolife-cry-stock-price.html.

Cryolife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.